Intercell presents V710 Phase II trial
The study, conducted by Intercell’s collaborator, a subsidiary of Merck, was designed to evaluate the safety and immunogenicity of V710 in patients with end-stage renal disease (ESRD) undergoing
China-based clinical-stage biotechnology company BoomRay Pharmaceuticals and Novartis Pharma have signed an exclusive worldwide licence deal for an undisclosed preclinical radioligand therapy (RLT) asset in a deal worth up to $900m.